Replies to post #3262 on Marker Therapeutics Inc (MRKR)

[Bio7mm]

You should read about why TPIV has a superior vaccine to Other approaches for HER2-neu. Glynn Wilson explains it well on the Tapimmune website. If Galena is valued at $438 million, Tapimmune will be valued at double that value when we get to Phase 3 testing.